Other Events ·
Vistagen expands executive severance plan to cover terminations outside change in control
VTGNVistagen Therapeutics, Inc.
The Board of Directors approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, effective October 7, 2026. The revised plan expands eligibility for involuntary termination benefits beyond transactions involving a Change in Control, allowing Eligible Employees to receive lump-sum cash payments based on monthly base salary and COBRA premiums following terminations without Cause or for Good Reason. All current executive officers are considered Eligible Employees under the updated terms. Vistagen Therapeutics is a clinical-stage biopharmaceutical company developing therapies for neurological disorders.